Xyphos Biosciences

Biotechnology ResearchCalifornia, United States2-10 Employees

Xyphos, a privately held biotechnology company, is focused on the creation and development of immuno-oncology therapeutics designed to harness the power of a patient’s immune system to cure cancer.
Xyphos’ novel and proprietary ACCEL (Advanced Cellular Control through Engineered Ligands) technology platform allows new and potentially better ways to mobilize and control engineered immune cells to find and destroy cancer cells. Xyphos’ first convertibleCAR-T cell product candidate is in preclinical development and is scheduled to be tested in a first-in-human clinical study in early 2020. Validating its approach, Xyphos entered in a collaboration with the Parker Institute for Cancer Immunotherapy to apply its ACCEL technology to novel cancer treatments.

Sign up for free to view info

Email Format Employee directory